Agilent Technologies, Inc. (NYSE:A) Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp decreased its position in Agilent Technologies, Inc. (NYSE:A) by 1.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 402,254 shares of the medical research company’s stock after selling 5,753 shares during the period. Boston Trust Walden Corp owned about 0.14% of Agilent Technologies worth $59,727,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in A. Wealth Enhancement Advisory Services LLC raised its position in shares of Agilent Technologies by 2.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 25,107 shares of the medical research company’s stock worth $3,653,000 after purchasing an additional 695 shares during the last quarter. Kathmere Capital Management LLC purchased a new stake in shares of Agilent Technologies in the first quarter valued at $243,000. Gibson Capital LLC acquired a new stake in shares of Agilent Technologies during the first quarter valued at $188,000. Diversified Trust Co increased its position in Agilent Technologies by 29.9% during the 1st quarter. Diversified Trust Co now owns 6,581 shares of the medical research company’s stock worth $958,000 after purchasing an additional 1,516 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. increased its position in Agilent Technologies by 25.0% during the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 211,253 shares of the medical research company’s stock worth $30,739,000 after purchasing an additional 42,291 shares in the last quarter. Hedge funds and other institutional investors own 87.42% of the company’s stock.

Agilent Technologies Stock Down 0.4 %

NYSE A traded down $0.50 on Friday, hitting $130.19. 1,248,591 shares of the stock traded hands, compared to its average volume of 1,685,121. The company has a market capitalization of $37.98 billion, a P/E ratio of 30.78, a price-to-earnings-growth ratio of 6.96 and a beta of 1.05. The stock has a 50-day moving average of $140.53 and a 200 day moving average of $138.43. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36. Agilent Technologies, Inc. has a twelve month low of $96.80 and a twelve month high of $155.35.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same period last year, the firm posted $1.43 EPS. The company’s revenue for the quarter was down 5.6% on a year-over-year basis. As a group, analysts expect that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were given a $0.236 dividend. This represents a $0.94 annualized dividend and a yield of 0.73%. The ex-dividend date was Tuesday, October 1st. Agilent Technologies’s dividend payout ratio is currently 22.22%.

Insider Buying and Selling at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now owns 24,118 shares in the company, valued at $3,497,110. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the sale, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at $3,497,110. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,995 shares of company stock valued at $1,739,510 in the last quarter. Corporate insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on A shares. TD Cowen raised their price objective on Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Barclays upped their price objective on Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a report on Tuesday, October 15th. Bank of America lifted their target price on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. Evercore ISI raised their price objective on Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Finally, Citigroup boosted their target price on Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $144.36.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.